Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by CONAGHAN, J. P.
Right arrow Articles by WARD-MCQUAID, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CONAGHAN, J. P.
Right arrow Articles by WARD-MCQUAID, J. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1966, Vol. 38, No. 5 345-354
© 1966 The Board of Management and Trustees of the British Journal of Anaesthesia

research-article

PENTAZOCINE AND PHENAZOCINE: A Double-Blind Comparison of Two Benzomorphan Derivatives in Postoperative Pain

J. P. CONAGHAN, M. JACOBSEN*, L. RAE and J. N. WARD-MCQUAID

Mansfield Group of Hospitals Nottinghamshire, England

The analgesic effeas of intramuscular injections of 30 and 45 mg pentazocine (Win 20, 228) were compared with 2 and 3 mg phenazocine (Narphen) in 128 patients with pain following abdominal surgery. Well-matched pairs of patients were allocated randomly to drugs. Pain was assessed under double-blind conditions, patients' assessments of relief were noted and vital capacity measurements were made. Both drugs were efficient for the relief of postoperative pain and did not cause nausea or vomiting. On average, 38 mg Win 20,228 was analgesically equivalent to 2.6 mg phenazocine. Changes in vital capacity gave a good indication of postoperative pain relief after both upper and lower abdominal operations. These changes were found to be significantly correlated with vital capacity before injection.

*Statistician, Bayer Products. Present address: Glaxo Laboratories Ltd., Ulverston, Lanes.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.